Business Context and Reporting Period
This Form 8-K was filed by Aquestive Therapeutics, Inc. on April 13, 2023. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Global Market under Item 8.01 Other Events.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock price rather than financial performance metrics.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq Listing Rule 5450(a)(1). Previously, on December 30, 2022, the company received notice of noncompliance because its common stock's minimum bid price fell below $1.00 per share for 30 consecutive business days. As of April 13, 2023, the company regained compliance after the minimum bid price met or exceeded $1.00 per share for ten consecutive business days.
Outlook, Risks, and Management Commentary
The filing confirms that the company had a compliance period of 180 calendar days, extending until June 28, 2023, to regain the required stock price. The company successfully met this requirement prior to the deadline. No additional guidance, risks, or unusual items were disclosed in this specific report.
Investor Verification Points
- Verify the current trading price of Aquestive Therapeutics (AQST) to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the company's most recent 10-K or 10-Q filings for financial health metrics, as this 8-K contains no financial data.
- Monitor future Nasdaq communications to confirm no new noncompliance notices are issued.